Arana Therapeutics, a unit of Cephalon, has inked an antibody research deal with Xoma, which gets a $6 million fee and unspecified milestones. "We selected Xoma because of their ability to provide a complete suite of validated technologies that will further enable us to accelerate our antibody development programs toward the clinic," said Steffen Nock, acting chief executive officer of Arana. Arana release